Subscribe

Paradigm Medical Industries, Inc. (PDMI)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Medical - Instruments & Supplies
Address 4273 South 590 West 84123
Salt Lake City, UT, US
CEO Charles S. Pritchard
IPO 1996-07-22
ISIN US69900Q8841

Explore sections of this company profile

Description

Paradigm Medical Industries, Inc. (PDMI) is a U.S.-based enterprise dedicated to the design, production, distribution, and sale of sophisticated medical instruments. These devices are primarily engineered for the timely diagnosis of glaucoma and a variety of other ocular conditions. The company's extensive product range addresses diverse ophthalmic diagnostic requirements. This includes biometric analyzers and A-scans like the P-2000 and P-2500 (which also function as pachymeters), along with P2700 and P37-II A/B scans. Paradigm also provides specialized blood flow analyzers, crucial for identifying and managing glaucoma and other retinal vascular disorders. Its offerings further extend to the P2200 pachymeter and the LD 500 and LD700 autoperimeters. For detailed corneal assessment, they feature the PARAVUE 300, suitable for both diagnostic imaging and contact lens fitting, and the SURVEYOR 500 for in-depth analysis of the cornea and anterior segment. The PARAMAX system, another key product, evaluates the functionality of ganglion cells to help identify individuals at risk of glaucoma. Additionally, Paradigm offers the P60 and P60 ACI ultrasound biomicroscopes, and the PARACAM 1000, a non-contact endothelial microscope. Complementing its hardware, the company also supplies essential software and various accessories. Paradigm Medical Industries was established in 1989 and operates from its headquarters in Salt Lake City, Utah.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.4K
Beta
-76.24
Float Shares
3.25B
Free Float %
100.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +0.00% +0.00% +0.00% +0.00% +0.00% -99.00% +1,150.00% +999,900.00% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-78.39
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Instruments & Supplies: +7.9%
    +6.3% Q1'09: -33.2% (vs Q1'08)
  • EPS growth Medical - Instruments & Supplies: +16.3%
    +51.0% Q1'09: +97.8% (vs Q1'08)
  • FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    -33.3% Q1'09: -54.2% (vs Q1'08)
  • EBIT margin Medical - Instruments & Supplies: +13.5%
    -42.2% Q1'09: -96.7% (vs Q1'08)
  • ROIC Medical - Instruments & Supplies: +6.0%
    Q1'09: +34.8% (vs Q1'08)
  • Share dilution Medical - Instruments & Supplies: +0.1%
    +0.0% Q1'09: +2,125.3% (vs Q1'08)
  • Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    -6.74× Q1'09: -3.30× (vs Q1'08)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-76.24) × ERP
WACC = 0% × Ke + 100% × Kd (6.8%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-320.5K
OE per share TTM
-2.22
Owner's Yield
-6,902.18%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
3.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-65.2K
Shares Outstanding
3.25B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Charles S. Pritchard Vice President of Sales and Marketing male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits